Buy Opto Circuits India; target of Rs 256: ICICIdirect.com

ICICIdirect.com is bullish on Opto Circuits India and has recommended buy rating on the stock with a target of Rs 256 in its August 17, 2012 research report.

“Opto Circuits’ Q1FY13 results were above our expectations. Revenues grew 36% YoY to Rs 715 crore, higher than our estimates of Rs 643 crore on the back of 1) 38.3% growth in the medical equipment & consumables segment, 2) 34% growth in the interventional devices segment and 3) favourable currency. After a sharp decline in Q4FY12, EBITDA margins normalised during the quarter. On a YoY basis, however, EBITDA margins declined 30 bps to 27.9%, higher than our estimates of 26.5%. The effective tax rate increased by 440 bps to 9.1%, which restricted net profit growth to 26.3% at Rs 147.0 crore. We are maintaining our BUY rating on the stock, although we will keep a watch on Crisil’s credit rating due in September amid the Icra rating downgrade confusion.”

“Revenues from the non-invasive segment grew 38% to Rs 583.5 crore on the back of new tenders, resumption of distribution of Powerheart AEDs in Japan and favourable currency. The invasive segment also registered healthy growth of 34% YoY to Rs 126 crore on the back of improved presence in geographies like China & Indonesia and favourable currency. The company is planning to launch a wearable Holter cardiac monitor MySense Heart device in the US market by the end of Q3FY13, for which it had received USFDA approval. It is also in discussions with some retail chains to market this product in the US. It is planning to set up a back end office, which is used for analysing the data from those machines.”

“We expect sales, EBITDA and PAT to grow at a CAGR of 22%, 20% and 18% (adjusted net profit base for FY12), respectively, in FY12-14E. Improvement in working capital management, which was visible in Q4, was reflected in Q1 as well, vindicating the progress on that front. New product launches in various geographies are expected to keep the growth momentum going. The shift of production to Vishakhapatnam and Malaysia is expected to compensate the pressure on margins on account of R&D charges to P&L henceforth. We have ascribed a value of Rs 256, based on 9x FY14E EPS of Rs 28.5. We maintain our BUY recommendation with a lightweight bias,” says ICICIdirect.com research report.

Institutional holding more than 40% in Indian cos

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment

Read More